trans-3-azido-8-methoxy-1,2,3,4-tetrahydronaphthalen-2-ol | 138053-06-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 英文名称: trans-3-azido-8-methoxy-1,2,3,4-tetrahydronaphthalen-2-ol
• 英文别名: (2S,3S)-3-azido-8-methoxy-1,2,3,4-tetrahydronaphthalen-2-ol
• CAS: 138053-06-2
• 化学式: C₁₁H₁₃N₃O₂
• 分子量: 219.243
• InChiKey: UBWTTWLNZFJDDO-UWVGGRQHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  43.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  trans-3-azido-8-methoxy-1,2,3,4-tetrahydronaphthalen-2-ol 在 palladium 10% on activated carbon lithium aluminium tetrahydride 、 乙基溴化镁 、 氢气 、 四丁基碘化铵 、 L-Selectride 、 sodium hydride 、 三乙胺 作用下， 以 四氢呋喃 、 乙醚 、 乙醇 、 二氧化碳 、 二乙胺 、 甲苯 为溶剂， 120.0 ℃ 、250.0 kPa 条件下， 反应 150.0h， 生成 (4aR,10aR)-8-formyl-9-hydroxy-2,3,4a,5,10,10a-hexahydro-naphtho[2,3-b][1,4]oxazine-4-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  [EN] NOVEL PHENOLIC AND CATECHOLIC AMINES AND PRODRUGS THEREOF
  [FR] NOUVELLES AMINES PHÉNOLIQUES ET CATÉCHOLIQUES ET LEURS PROMÉDICAMENTS

  摘要：

  本发明涉及一种新型酚和儿茶酚胺，其化学式为1，以及它们的制备方法、含有它们的药物组合物，它们在治疗中的应用，以及它们以正电子发射断层扫描（PET）或单光子发射计算机断层扫描（SPECT）配体形式的应用。

  公开号：

  WO2009156458A1
• 作为产物：
  描述：

  5-甲氧基-1,4-二氢萘 在 sodium azide 、 硫酸 、 间氯过氧苯甲酸 作用下， 以 二氯甲烷 、 二甲基亚砜 为溶剂， 反应 30.0h， 生成 trans-3-azido-8-methoxy-1,2,3,4-tetrahydronaphthalen-2-ol
  参考文献：
  名称：

  Centrally acting .alpha.1-adrenoceptor agonists based on hexahydronaphth[2,3-b]-1,4-oxazines and octahydrobenzo[g]quinolines

  摘要：

  Centrally acting alpha(1)-agonists may be of therapeutic value in dementias and other CNS disorders characterized by symptoms of noradrenergic insufficiency. Therefore, on the basis of known peripherally acting alpha(1)-agonists two new groups of centrally acting alpha(1)-agonists with improved lipophilicity, the hexahydronaphth[2,3-b]-1,4-oxazines type A and the octahydrobenzo[g]quinolines type B were designed. The N-methylated derivatives 14 and 33 demonstrate potent, direct agonistic activity at postjunctional alpha(1)-receptors. Ring substituent alterations in compounds of type A and B change the potency of compounds on the rabbit ear artery by over 3 orders of magnitude (pD2 = 5.35-8.40). The efficacy of these compounds varies from 42 to 110%. These alpha(1)-agonists which were selective in the pithed rat increase vigilance in rats. Compound 14 was found to be a centrally acting alpha(1)-agonist with good tolerability in different animal species and in healthy volunteers. Furthermore, 14 selectively stimulates the breakdown of phosphatidylinositol in rat cerebral cortex slices. In vivo, the compound reverses behavioral deficits in animals which received noradrenergic lesions following DDC or DSP4 treatment. Oxazine 14 and its close derivatives are by far more lipophilic than commonly known alpha(1)-agonists. This is demonstrated in a ClogP-PROBIS plot.

  DOI：

  10.1021/jm00081a008

文献信息

• NOVEL PHENOLIC AND CATECHOLIC AMINES AND PRODRUGS THEREOF
  申请人：PUSCHL Ask

  公开号：US20090325946A1

  公开（公告）日：2009-12-31

  The present invention relates to novel phenolic and catecholic amines of Formula I, to processes for their preparation, pharmaceutical compositions containing them, to their use in therapy and to their use in radiolabeled form as PET- or SPECT ligands.

  本发明涉及一种新型的具有化学式I的酚胺和儿茶酚胺，以及它们的制备方法、含有它们的药物组合物、在治疗中的应用以及作为PET或SPECT配体的放射标记形式的应用。
• Centrally acting .alpha.1-adrenoceptor agonists based on hexahydronaphth[2,3-b]-1,4-oxazines and octahydrobenzo[g]quinolines
  作者：Joachim Nozulak、Jean M. Vigouret、Anne L. Jaton、Alfred Hofmann、Anant R. Dravid、Hans P. Weber、Hans O. Kalkman、Malcolm D. Walkinshaw

  DOI：10.1021/jm00081a008

  日期：1992.2

  Centrally acting alpha(1)-agonists may be of therapeutic value in dementias and other CNS disorders characterized by symptoms of noradrenergic insufficiency. Therefore, on the basis of known peripherally acting alpha(1)-agonists two new groups of centrally acting alpha(1)-agonists with improved lipophilicity, the hexahydronaphth[2,3-b]-1,4-oxazines type A and the octahydrobenzo[g]quinolines type B were designed. The N-methylated derivatives 14 and 33 demonstrate potent, direct agonistic activity at postjunctional alpha(1)-receptors. Ring substituent alterations in compounds of type A and B change the potency of compounds on the rabbit ear artery by over 3 orders of magnitude (pD2 = 5.35-8.40). The efficacy of these compounds varies from 42 to 110%. These alpha(1)-agonists which were selective in the pithed rat increase vigilance in rats. Compound 14 was found to be a centrally acting alpha(1)-agonist with good tolerability in different animal species and in healthy volunteers. Furthermore, 14 selectively stimulates the breakdown of phosphatidylinositol in rat cerebral cortex slices. In vivo, the compound reverses behavioral deficits in animals which received noradrenergic lesions following DDC or DSP4 treatment. Oxazine 14 and its close derivatives are by far more lipophilic than commonly known alpha(1)-agonists. This is demonstrated in a ClogP-PROBIS plot.
• US4656167A
  申请人：——

  公开号：US4656167A

  公开（公告）日：1987-04-07
• US8067410B2
  申请人：——

  公开号：US8067410B2

  公开（公告）日：2011-11-29
• Synthesis and SAR study of a novel series of dopamine receptor agonists
  作者：Rune Risgaard、Martin Jensen、Morten Jørgensen、Benny Bang-Andersen、Claus T. Christoffersen、Klaus G. Jensen、Jesper L. Kristensen、Ask Püschl

  DOI：10.1016/j.bmc.2013.11.012

  日期：2014.1

  The synthesis of a novel series of dopamine receptor agonists are described as well as their in vitro potency and efficacy on dopamine D-1 and D-2 receptors. This series was designed from pergolide and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[g] quinolin-6-ol (PHBQ) and resulted in the synthesis of (2R,4aR,10aR)-2-methylsulfanylmethyl-4-propyl-3,4,4a,5,10,10a-hexahydro-2H-naphtho[2,3-b][1,4]oxazin-9-ol (compound 27), which has a D-1 and D-2 receptor profile similar to that of the most recently approved drug for Parkinson's disease, rotigotine. (C)2013 Elsevier Ltd. All rights reserved.